Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity

mAbs

Volumn 7, Issue 4, 2015, Pages 662-671

  van Schie, Karin A ^a,b   Wolbink, Gerrit Jan ^a,b,c   Rispens, Theo ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Department of Pediatric Rheumatology   (Netherlands)

Author keywords

Allotype; Anti drug antibodies (ADA); Glycan; Idiotype; Immunogenicity; Pre existing antibodies; Rheumatoid factor

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALLOANTIBODY; ANTI GLYCAN ANTIBODY; ANTI HINGE ANTIBODY; ANTI ISOTYPE ANTIBODY; ANTIBODY; ANTIIDIOTYPIC ANTIBODY; CERTOLIZUMAB PEGOL; CETUXIMAB; GLYCOPROTEIN; GOLIMUMAB; GSK 1995057; HETEROPHILE ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; NATALIZUMAB; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RHEUMATOID FACTOR; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY REACTIVITY; ANTIBODY RESPONSE; ANTIBODY STRUCTURE; BINDING AFFINITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CROSS REACTION; DRUG BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; NONHUMAN; REVIEW; SENSITIVITY AND SPECIFICITY; IMMUNOLOGY;

ANTIBODIES; CROSS REACTIONS; HUMANS;

EID: 84944627318     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1048411     Document Type: Review

References (109)

1. Chatenoud L, Jonker M, Villemain F, Goldstein G, Bach JF. The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science 1986; 232: 1406-1408; PMID: 3086976; http://dx. doi. org/10. 1126/science. 3086976.
2. Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995; 32: 1271-1281; PMID: 8559151; http://dx. doi. org/10. 1016/0161-5890(95)00085-2.
3. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010; 2: 256-265; PMID: 20400861; http://dx. doi. org/10. 4161/mabs. 2. 3. 11641.
4. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 164-172; PMID: 23399692; http://dx. doi. org/10. 1038/nrrheum. 2013. 4.
5. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165-178; http://dx. doi. org/10. 1136/annrheumdis-2012-202545.
6. Somerfield J, Hill-Cawthorne GA, Lin A, Zandi MS, McCarthy C, Jones JL, Willcox M, Shaw D, Thompson SA, Compston AS, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 2010; 185: 763-768; http://dx. doi. org/10. 4049/jimmunol. 1000422.
7. Krieckaert CL, Bartelds GM, Wolbink GJ. Therapy: Immunogenicity of biologic therapies-we need tolerance. Nat Rev Rheumatol 2010; 6: 558-559.
8. Benjamin RJ, Cobbold SP, Clark MR, Waldmann H. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med 1986; 163: 1539-1552; http://dx. doi. org/10. 1084/jem. 163. 6. 1539.
9. Gilliland LK, Walsh LA, Frewin MR, Wise MP, Tone M, Hale G, Kioussis D, Waldmann H. Elimination of the immunogenicity of therapeutic antibodies. J Immunol 1999; 162: 3663-3671.
10. Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis 2013; 5: 561-574; PMID: 23425272; http://dx. doi. org/10. 4155/bio. 13. 6.
11. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol 2012; 24: 306-311; http://dx. doi. org/10. 1097/BOR. 0b013e3283521c4e.
12. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008; 48: 1267-1281; http://dx. doi. org/10. 1016/j. jpba. 2008. 09. 020.
13. Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014; 16: 658-673; PMID: 24764037; http://dx. doi. org/10. 1208/s12248-014-9599-2.
14. Jerne NK. The generative grammar of the immune system. Science 1985; 229: 1057-1059; PMID: 4035345; http://dx. doi. org/10. 1126/science. 4035345.
15. Nisonoff A. On the nomenclature for V-region serological markers. Immunol Today 1995; 16: 191-193; PMID: 7734047; http://dx. doi. org/10. 1016/0167-5699(95)80120-0.
16. Jefferis R. Nomenclature of V-region markers. Immunol Today 1995; 16: 207-208; PMID: 7734050; http://dx. doi. org/10. 1016/0167-5699(95)80123-5.
17. Jefferis R. What is an idiotype? Immunol Today 1993; 14: 119-121; PMID: 8466627; http://dx. doi. org/10. 1016/0167-5699(93)90211-3.
18. Kazatchkine MD, Coutinho A. Are lymphocytes concerned with our definition of idiotypes? Immunol Today 1993; 14: 513-515; PMID: 8274191; http://dx. doi. org/10. 1016/0167-5699(93)90268-P.
19. Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013; 19: 593-600; http://dx. doi. org/10. 1177/1352458512460604.
20. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de GE, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-715; PMID: 16508927; http://dx. doi. org/10. 1002/art. 21671.
21. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-1745; http://dx. doi. org/10. 1136/ard. 2008. 092833.
22. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and antiinfliximab antibodies. Rheumatology (Oxford) 2007; 46: 1828-1834; PMID: 18032541; http://dx. doi. org/10. 1093/rheumatology/kem261.
23. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, LemsWF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term followup. JAMA 2011; 305: 1460-1468; PMID: 21486979; http://dx. doi. org/10. 1001/jama. 2011. 406.
24. Lecluse LL, Driessen RJ, Spuls PI, De Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-132.
25. van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015; 74: 311-314; http://dx. doi. org/10. 1136/annrheumdis-2014-206237.
26. van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie KA, Hart MH, de Jong RN, van Buren EE, van HM, Aarden L, Wolbink G, et al. Functional Analysis of the Anti-adalimumab Response Using Patientderived Monoclonal Antibodies. J Biol Chem 2014; 289: 34482-34488; http://dx. doi. org/10. 1074/jbc. M114. 615500.
27. van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de GE, Hart M, van Ham SM, Rispens T, Aarden L, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013; 72: 104-109; http://dx. doi. org/10. 1136/annrheumdis-2012-201445.
28. Tatarewicz SM, Juan G, Swanson SJ, Moxness MS. Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17, 1 allotype. J Immunol Methods 2012; 382: 93-100; PMID: 22609464; http://dx. doi. org/10. 1016/j. jim. 2012. 05. 009.
29. Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, Cordy JC, Lipson DA, Bayliffe AI. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol 2013; 33: 1192-1203; http://dx. doi. org/10. 1007/s10875-013-9915-0.
30. Weeraratne D, Chen A, Pennucci JJ, Wu CY, Zhang K, Wright J, Perez-Ruixo JJ, Yang BB, Kaliyaperumal A, Gupta S, et al. Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol 2011; 11: 17.
31. Szolar OH, Stranner S, Zinoecker I, Mudde GC, Himmler G, Waxenecker G, Nechansky A. Qualification and application of a surface plasmon resonancebased assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody. J Pharm Biomed Anal 2006; 41: 1347-1353; http://dx. doi. org/10. 1016/j. jpba. 2006. 03. 026.
32. Sasso EH, Barber CV, Nardella FA, Yount WJ, Mannik M. Antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors. The C gamma 2-C gamma 3 interface region contains the major determinants. J Immunol 1988; 140: 3098-3107; PMID: 2452199.
33. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004; 16: 246-253; http://dx. doi. org/10. 1097/00002281-200405000-00013.
34. Mierau R, Genth E. Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis. Clin Chem Lab Med 2006; 44: 138-143; PMID: 16475897; http://dx. doi. org/10. 1515/CCLM. 2006. 026.
35. Westwood OM, Nelson PN, Hay FC. Rheumatoid factors: what's new? Rheumatology (Oxford) 2006; 45: 379-385; PMID: 16418203; http://dx. doi. org/10. 1093/rheumatology/kei228.
36. Van Snick JL, Van RE, Markowetz B, Cambiaso CL, Masson PL. Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen-antibody complexes. Eur J Immunol 1978; 8: 279-285; PMID: 668802; http://dx. doi. org/10. 1002/eji. 1830080412.
37. Ng YC, Peters DK, Walport MJ. Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum 1988; 31: 99-107; PMID: 3345233; http://dx. doi. org/10. 1002/art. 1780310114.
38. Xue L, Rup B. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J 2013; 15: 893-896; PMID: 23761225; http://dx. doi. org/10. 1208/s12248-013-9497-z.
39. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G. Decrease of anticyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63: 1218-1221; PMID: 15361374; http://dx. doi. org/10. 1136/ard. 2003. 014647.
40. Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van SD, Dijkmans BA, Nurmohamed MT. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 1972-1977; PMID: 18785316.
41. De RL, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, De KF. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 299-302; PMID: 15166003; http://dx. doi. org/10. 1136/ard. 2004. 023523.
42. Mendonca JA, Marques-Neto JF, Samara AM, Appenzeller S. Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis. Rheumatol Int 2012; 32: 815-818; PMID: 21327431; http://dx. doi. org/10. 1007/s00296-011-1812-3.
43. Faillace C, de Carvalho JF. Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis. Rheumatol Int 2013; 33: 1909-1910; PMID: 22441966; http://dx. doi. org/10. 1007/s00296-012-2409-1.
44. Jones JD, Shyu I, Newkirk MM, Rigby WF. A rheumatoid factor paradox: inhibition of rituximab effector function. Arthritis Res Ther 2013; 15: R20; PMID: 23351360; http://dx. doi. org/10. 1186/ar4152.
45. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordstrom DC, Gomez-Reino J, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575-1580; PMID: 21571731; http://dx. doi. org/10. 1136/ard. 2010. 148759.
46. Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum 2013; 43: 9-17; PMID: 23290690; http://dx. doi. org/10. 1016/j. semarthrit. 2012. 11. 007.
47. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72: 517-524; PMID: 22562972; http://dx. doi. org/10. 1136/annrheumdis-2011-201244.
48. Song SN, Yoshizaki K. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin Drug Metab Toxicol 2015; 11: 307-316; PMID: 25491492; http://dx. doi. org/10. 1517/17425255. 2015. 992779.
49. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008; 20: 431-435; PMID: 18619538; http://dx. doi. org/10. 1016/j. coi. 2008. 06. 011.
50. Rispens T, de VH, de GE, Wouters D, Stapel S, Wolbink GJ, Aarden LA. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods 2012; 375: 93-99; PMID: 21986105; http://dx. doi. org/10. 1016/j. jim. 2011. 09. 011.
51. Tatarewicz S, Miller JM, Swanson SJ, Moxness MS. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J Immunol Methods 2010; 357: 10-16; PMID: 20347831; http://dx. doi. org/10. 1016/j. jim. 2010. 03. 012.
52. Stubenrauch K, Wessels U, Vogel R, Schleypen J. Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. Anal Biochem 2009; 390: 189-196; PMID: 19379704; http://dx. doi. org/10. 1016/j. ab. 2009. 04. 021.
53. Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol 2009; 132: 334-341; PMID: 19502112; http://dx. doi. org/10. 1016/j. clim. 2009. 05. 007.
54. Vaisanen V, Peltola MT, Lilja H, Nurmi M, Pettersson K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem 2006; 78: 7809-7815; PMID: 17105175; http://dx. doi. org/10. 1021/ac061201+.
55. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010; 32: 1597-1609; PMID: 20974317; http://dx. doi. org/10. 1016/j. clinthera. 2010. 07. 021.
56. Araujo J, Zocher M, Wallace K, Peng K, Fischer SK. Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody. J Pharm Biomed Anal 2011; 55: 1041-1049; PMID: 21466939; http://dx. doi. org/10. 1016/j. jpba. 2011. 03. 008.
57. de Lange GG. Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp Clin Immunogenet 1989; 6: 7-17; PMID: 2698222.
58. Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 2009; 1: 332-338; PMID: 20073133; http://dx. doi. org/10. 4161/mabs. 1. 4. 9122.
59. Jerne D. Antibody suppression and antiallotype antibodies. II. Interference of circulating antiallotype antibodies with prophylactic treatment against Rh sensitization. Scand J Immunol 1976; 5: 1085-1088; PMID: 827012; http://dx. doi. org/10. 1111/j. 1365-3083. 1976. tb03061. x.
60. Fudenberg HH, Fudenberg BR. Antibody to hereditary human gamma-globulin (gm) factor resulting from maternal-fetal incompatibility. Science 1964; 145: 170-171; PMID: 14171557; http://dx. doi. org/10. 1126/science. 145. 3628. 170.
61. Stickler MM, Reddy A, Xiong JM, Hinton PR, DuBridge R, Harding FA. The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site. Genes Immun 2011; 12: 213-221; PMID: 21326320; http://dx. doi. org/10. 1038/gene. 2010. 68.
62. Bartelds GM, de GE, Nurmohamed MT, Hart MH, van Eede PH, Wijbrandts CA, Crusius JB, Dijkmans BA, Tak PP, Aarden L, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther 2010; 12: R221; PMID: 21187010; http://dx. doi. org/10. 1186/ar3208.
63. Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, Ohresser M, Degenne D, Dugoujon JM, Jefferis R, Rutgeerts P, Lefranc MP, Watier H. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics 2009; 19: 383-387; PMID: 19319024; http://dx. doi. org/10. 1097/FPC. 0b013e32832a06bf.
64. Milner EC, Hufnagle WO, Glas AM, Suzuki I, Alexander C. Polymorphism and utilization of human VH Genes. Ann N Y Acad Sci 1995; 764: 50-61; PMID: 7486575; http://dx. doi. org/10. 1111/j. 1749-6632. 1995. tb55806. x.
65. Watson CT, Breden F. The immunoglobulin heavy chain locus: genetic variation, missing data, and implications for human disease. Genes Immun 2012; 13: 363-373; PMID: 22551722; http://dx. doi. org/10. 1038/gene. 2012. 12.
66. Klee GG. Human anti-mouse antibodies. Arch Pathol Lab Med 2000; 124: 921-923; PMID: 10835540.
67. Koshida S, Asanuma K, Kuribayashi K, Goto M, Tsuji N, Kobayashi D, Tanaka M, Watanabe N. Prevalence of human anti-mouse antibodies (HAMAs) in routine examinations. Clin Chim Acta 2010; 411: 391-394; PMID: 20006593; http://dx. doi. org/10. 1016/j. cca. 2009. 12. 006.
68. Kaplan IV, Levinson SS. When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. Clin Chem 1999; 45: 616-618; PMID: 10222346.
69. Potter KN, Li Y, Mageed RA, Jefferis R, Capra JD. Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8. Scand J Immunol 1999; 50: 14-20; PMID: 10404046; http://dx. doi. org/10. 1046/j. 1365-3083. 1999. 00524. x.
70. Mageed RA, Dearlove M, Goodall DM, Jefferis R. Immunogenic and antigenic epitopes of immunoglobulins. XVII-Monoclonal antibodies reactive with common and restricted idiotopes to the heavy chain of human rheumatoid factors. Rheumatol Int 1986; 6: 179-183; PMID: 2431452; http://dx. doi. org/10. 1007/BF00541285.
71. Potter KN, Li Y, Mageed RA, Jefferis R, Capra JD. Anti-idiotypic antibody D12 and superantigen SPA both interact with human VH3-encoded antibodies on the external face of the heavy chain involving FR1, CDR2 and FR3. Mol Immunol 1998; 35: 1179-1187; PMID: 10199392; http://dx. doi. org/10. 1016/S0161-5890(98)00103-5.
72. LegendreC, KreisH, Bach JF, Chatenoud L. Prediction of successful allograft rejection retreatment with OKT3. Transplantation 1992; 53: 87-90; PMID: 1733090; http://dx. doi. org/10. 1097/00007890-199201000-00016.
73. Ott MG, Marme F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 2012; 130: 2195-2203; PMID: 21702044; http://dx. doi. org/10. 1002/ijc. 26258.
74. Mirick GR, Bradt BM, DeNardo SJ, DeNardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004; 48: 251-257; PMID: 15640788.
75. DeNardo GL, Bradt BM, Mirick GR, DeNardo S. Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 2003; 52: 309-316; PMID: 12700946.
76. Brezski RJ, Knight DM, Jordan RE. The origins, specificity, and potential biological relevance of human anti-IgG hinge autoantibodies. Sci World J 2011; 11: 1153-1167; PMID: 21623461; http://dx. doi. org/10. 1100/tsw. 2011. 107.
77. Brezski RJ, Luongo JL, Petrone D, Ryan MH, Zhong D, Tam SH, Schmidt AP, Kruszynski M, Whitaker BP, Knight DM, Jordan RE. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol 2008; 181: 3183-3192; PMID: 18713989; http://dx. doi. org/10. 4049/jimmunol. 181. 5. 3183.
78. Osterland CK, Harboe M, Kunkel HG. Anti-gammaglobulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang 1963; 8: 133-152; PMID: 13940587; http://dx. doi. org/10. 1111/j. 1423-0410. 1963. tb03290. x.
79. Mellbye OJ, Natvig JB. Evidence for immune complexes containing antibody to the pepsin site of IgG in rheumatoid synovial fluids. Clin Exp Immunol 1971; 8: 889-899; PMID: 4933318.
80. Terness P, Kohl I, Hubener G, Battistutta R, Moroder L, Welschof M, Dufter C, Finger M, Hain C, Jung M. The natural human IgG anti-F(ab')2 antibody recognizes a conformational IgG1 hinge epitope. J Immunol 1995; 154: 6446-6452; PMID: 7539020.
81. Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?. MAbs 2010; 2: 212-220; PMID: 20400859; http://dx. doi. org/10. 4161/mabs. 2. 3. 11780.
82. Brezski RJ, Kinder M, Grugan KD, Soring KL, Carton J, Greenplate AR, Petley T, Capaldi D, Brosnan K, Emmell E, et al. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. MAbs 2014; 6: 1265-1273; PMID: 25517311; http://dx. doi. org/10. 4161/mabs. 29825.
83. van de Stadt LA, de VH, Derksen NI, Brouwer M, Wouters D, van SD, Wolbink G, Rispens T. Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheumatol 2014; 66: 1133-1140; PMID: 24782178; http://dx. doi. org/10. 1002/art. 38335.
84. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 2013; 30: 1729-1734; PMID: 23673554; http://dx. doi. org/10. 1007/s11095-013-1067-7.
85. Verhoef JJ, Carpenter JF, Anchordoquy TJ, Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today 2014; 19: 1945-1952; PMID: 25205349; http://dx. doi. org/10. 1016/j. drudis. 2014. 08. 015.
86. Dery JP, Braden GA, Lincoff AM, Kereiakes DJ, Browne K, Little T, George BS, Sane DC, Cines DB, Effron MB, Mascelli MA, Langrall MA, Damaraju L, Barnathan ES, Tcheng JE. Final results of the ReoPro readministration registry. Am J Cardiol 2004; 93: 979-984; PMID: 15081439; http://dx. doi. org/10. 1016/j. amjcard. 2003. 12. 051.
87. Lajus S, Clofent-Sanchez G, Jais C, Coste P, Nurden P, Nurden A. Thrombocytopenia after abciximab use results from different mechanisms. Thromb Haemost 2010; 103: 651-661; PMID: 20076853; http://dx. doi. org/10. 1160/TH09-08-0603.
88. Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, Coscas D, Bar-Meir S, Goldstein I, Chowers Y. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-48; PMID: 20519742; http://dx. doi. org/10. 1136/gut. 2009. 201533.
89. Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 1172-1183; PMID: 23650912; http://dx. doi. org/10. 1111/apt. 12330.
90. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014; 5: 520; PMID: 25368619; http://dx. doi. org/10. 3389/fimmu. 2014. 00520.
91. Lammerts van Bueren JJ, Rispens T, Verploegen S, Palen-Merkus T, Stapel S, Workman LJ, James H, van Berkel PH, van de Winkel JG, Platts-Mills TA, Parren PW. Anti-galactose-α-1, 3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol 2011; 29: 574-576; PMID: 21747378; http://dx. doi. org/10. 1038/nbt. 1912.
92. Galili U. The a-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol 2005; 83: 674-686; PMID: 16266320; http://dx. doi. org/10. 1111/j. 1440-1711. 2005. 01366. x.
93. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with antiα-galactosyl specificity. J Exp Med 1984; 160: 1519-1531; PMID: 6491603; http://dx. doi. org/10. 1084/jem. 160. 5. 1519.
94. Rispens T, Derksen NI, Commins SP, Platts-Mills TA, Aalberse RC. IgE production to α-gal is accompanied by elevated levels of specific IgG1 antibodies and low amounts of IgE to blood group B. PLoS ONE 2013; 8: e55566; PMID: 23390540; http://dx. doi. org/10. 1371/journal. pone. 0055566.
95. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 2007; 364: 8-18; PMID: 17362871; http://dx. doi. org/10. 1016/j. ab. 2007. 01. 023.
96. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1, 3-galactose. N Engl J Med 2008; 358: 1109-1117; PMID: 18337601; http://dx. doi. org/10. 1056/NEJMoa074943.
97. Commins SP, James HR, Kelly LA, Pochan SL, Workman LJ, Perzanowski MS, Kocan KM, Fahy JV, Nganga LW, Ronmark E, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1, 3-galactose. J Allergy Clin Immunol 2011; 127: 1286-1293; PMID: 21453959; http://dx. doi. org/10. 1016/j. jaci. 2011. 02. 019.
98. Nezlin R. Interactions between immunoglobulin G molecules. Immunol lett 2010; 132(1-2): 1-5; PMID: 20600325.
99. Butler JE, Ni L, Brown WR, Joshi KS, Chang J, Rosenberg B, Voss EW, Jr. The immunochemistry of sandwich ELISAs-VI. Greater than 90% of monoclonal and 75% of polyclonal anti-fluorescyl capture antibodies (CAbs) are denatured by passive adsorption. Mol Immunol 1993; 30: 1165-1175; PMID: 8413321; http://dx. doi. org/10. 1016/0161-5890(93)90135-X.
100. Qian W, Yao D, Yu F, Xu B, Zhou R, Bao X, Lu Z. Immobilization of antibodies on ultraflat polystyrene surfaces. Clin Chem 2000; 46: 1456-1463; PMID: 10973890.
101. Rispens T, Ooievaar-De HP, Vermeulen E, Schuurman J, van der Neut KM, Aalberse RC. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J Immunol 2009; 182: 4275-4281; PMID: 19299726; http://dx. doi. org/10. 4049/jimmunol. 0804338.
102. Rispens T, Meesters J, den Bleker TH, Ooijevaar-de HP, Schuurman J, Parren PW, Labrijn A, Aalberse RC. Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. Mol Immunol 2013; 53: 35-42.
103. Rispens T, Davies AM, Ooijevaar-de HP, Absalah S, Bende O, Sutton BJ, Vidarsson G, Aalberse RC. Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J Biol Chem 2014; 289: 6098-6109; PMID: 24425871; http://dx. doi. org/10. 1074/jbc. M113. 541813.
104. Ito T, Kitahara K, Umemura T, Ota M, Shimozuru Y, Kawa S, Bahram S. A novel heterophilic antibody interaction involves IgG4. Scand J Immunol 2010; 71: 109-114; PMID: 20384862; http://dx. doi. org/10. 1111/j. 1365-3083. 2009. 02353. x.
105. Zack DJ, Stempniak M, Wong AL, Weisbart RH. Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. J Immunol 1995; 155: 5057-5063; PMID: 7594514.
106. Ewert S, Huber T, Honegger A, Pluckthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325: 531-553; PMID: 12498801; http://dx. doi. org/10. 1016/S0022-2836(02)01237-8.
107. McMahon MJ, O'Kennedy R. Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J Immunol Methods 2000; 241: 1-10; PMID: 10915844; http://dx. doi. org/10. 1016/S0022-1759(00)00196-4.
108. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343: 1260-1263; PMID: 24626930; http://dx. doi. org/10. 1126/science. 1248943.
109. An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs 2009; 1: 572-579; PMID: 20073128; http://dx. doi. org/10. 4161/mabs. 1. 6. 10185.